New diabetes pill shows Real-World promise in italian study
NCT ID NCT05230615
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study followed 458 adults with type 2 diabetes in Italy who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers tracked changes in blood sugar levels and body weight over about 8-10 months. The goal was to see how well the medication works in real-world settings, not a controlled lab environment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS MultiMedica
Sesto San Giovanni, Italy
-
Master Centre for Italy
Rome, 00144, Italy
Conditions
Explore the condition pages connected to this study.